Neuraly Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 18

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Neuraly General Information

Description

Operator of a clinical-stage biotechnology company intended to translate scientific discoveries in neurology into new drugs. The company discovers and develops revolutionary treatments for neurodegenerative diseases, and offers a clinical development strategy focusing on the inhibition of pathological glial activation and its role in preventing neuronal cell death, thereby enabling people suffering from the devastating consequences of diseases such as Parkinson's disease (PD), and Alzheimer's disease (AD) to improve their living.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 704 Quince Orchard Road
  • Suite 320
  • Gaithersburg, MD 20878
  • United States
+1 (240)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 704 Quince Orchard Road
  • Suite 320
  • Gaithersburg, MD 20878
  • United States
+1 (240)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neuraly Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 01-Jan-2019 Completed Generating Revenue
3. Early Stage VC (Series A) 18-Jul-2018 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 01-Jan-2016 Completed Startup
To view Neuraly’s complete valuation and funding history, request access »

Neuraly Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
Series A-1
To view Neuraly’s complete cap table history, request access »

Neuraly Patents

Neuraly Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4705331-A1 Glucagon-like peptide-1 receptor agonist variants and methods thereof Pending 01-May-2023
US-20260295054-A1 Glucagon-like peptide-1 receptor agonist variants and methods thereof Pending 01-May-2023
WO-2024229006-A1 Glucagon-like peptide-1 receptor agonist variants and methods thereof Inactive 01-May-2023
US-20240374691-A1 Glp-1r agonists for use in a treatment of neurologial impairment associated with viral infection Pending 25-Aug-2021
WO-2023028554-A1 Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection Inactive 25-Aug-2021 A61K38/26
To view Neuraly’s complete patent history, request access »

Neuraly Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neuraly Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Boston Harbor Angels Angel Group Minority
Dongkoo Bio&Pharma Corporation Minority
Geon Investment Venture Capital Minority
InterVest Venture Capital Minority
Johns Hopkins Technology Ventures Accelerator/Incubator
You’re viewing 5 of 10 investors. Get the full list »

Neuraly Investments (1)

Neuraly’s most recent deal was a Joint Venture with Zentera Alpha. The deal was made on 01-Jan-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Zentera Alpha 01-Jan-2022 Joint Venture Drug Discovery
To view Neuraly’s complete investments history, request access »

Neuraly FAQs

  • When was Neuraly founded?

    Neuraly was founded in 2016.

  • Where is Neuraly headquartered?

    Neuraly is headquartered in Gaithersburg, MD.

  • What is the size of Neuraly?

    Neuraly has 18 total employees.

  • What industry is Neuraly in?

    Neuraly’s primary industry is Drug Discovery.

  • Is Neuraly a private or public company?

    Neuraly is a Private company.

  • What is Neuraly’s current revenue?

    The current revenue for Neuraly is .

  • How much funding has Neuraly raised over time?

    Neuraly has raised $36M.

  • Who are Neuraly’s investors?

    Boston Harbor Angels, Dongkoo Bio&Pharma, Geon Investment, InterVest, and Johns Hopkins Technology Ventures are 5 of 10 investors who have invested in Neuraly.

  • When was Neuraly acquired?

    Neuraly was acquired on 01-Jan-2019.

  • Who acquired Neuraly?

    Neuraly was acquired by D&D Pharmatech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process